China Pharma Holdings, Inc.
$0.67
▼
-1.56%
2026-04-21 06:11:01
www.chinapharmaholdings.com
ASE: CPHI
Explore China Pharma Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$26.84 M
Current Price
$0.67
52W High / Low
$2.6 / $0.5
Stock P/E
—
Book Value
$1.47
Dividend Yield
—
ROCE
-46.43%
ROE
-20.91%
Face Value
—
EPS
$-7.4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
215
Beta
1.09
Debt / Equity
17.09
Current Ratio
0.32
Quick Ratio
0.1
Forward P/E
—
Price / Sales
6.32
Enterprise Value
$29.72 M
EV / EBITDA
-18.76
EV / Revenue
7.17
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Dr. Reddy's Laboratories Limited | $12.97 | 17.86 | $11.1 B | 0.65% | 19.86% | 16.1% | $1,379.7 / $1,129 | $4.78 |
| 2. | Collegium Pharmaceutical, Inc. | $34.31 | 17.33 | $1.09 B | — | 14.67% | 23.7% | $50.79 / $25.86 | $9.51 |
| 3. | Akebia Therapeutics, Inc. | $1.43 | — | $381.73 M | — | 11% | 64.49% | $4.08 / $1.14 | $0.12 |
| 4. | Gelteq Limited | $0.7 | — | $7.5 M | — | -31.25% | -42.99% | $4.11 / $0.64 | $1.09 |
| 5. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 6. | Pacira BioSciences, Inc. | $24.9 | 143.33 | $1.01 B | — | 2.91% | 0.96% | $27.64 / $18.8 | $16.86 |
| 7. | Lantheus Holdings, Inc. | $83.97 | 23.41 | $5.47 B | — | 16.66% | 21.45% | $108.91 / $47.25 | $16.87 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.23 M | 0.76 M | 1.03 M | 1.14 M | 1.13 M | — |
| Operating Profit | -1.2 M | -0.63 M | -0.5 M | -0.76 M | -1.19 M | — |
| Net Profit | -1.22 M | -0.65 M | -0.53 M | -0.79 M | -1.22 M | — |
| EPS in Rs | -0.03 | -0.02 | -0.01 | -0.02 | -0.03 | -0.65 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.14 M | 4.53 M | 7.01 M | 8.1 M |
| Operating Profit | -3.09 M | -4.58 M | -2.77 M | -3.64 M |
| Net Profit | -3.19 M | -4.74 M | -3.08 M | -3.97 M |
| EPS in Rs | -0.08 | -0.12 | -0.08 | -0.1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 31 M | 14.89 M | 16.47 M | 17.78 M |
| Total Liabilities | 8.26 M | 7.14 M | 9.01 M | 13.49 M |
| Equity | 22.74 M | 7.75 M | 7.45 M | 4.29 M |
| Current Assets | 2.35 M | 3.27 M | 6 M | 5.96 M |
| Current Liabilities | 7.4 M | 5.02 M | 6.82 M | 12.74 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 0.15 M | -0.41 M | -0.7 M | -0.41 M |
| Investing CF | -0.14 M | -0.29 M | -0.01 M | -0.4 M |
| Financing CF | -0.29 M | -0.03 M | 0.07 M | -1.77 M |
| Free CF | 0.01 M | -0.7 M | -0.71 M | -0.81 M |
| Capex | -0.14 M | -0.29 M | -0.01 M | -0.4 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -8.49% | -35.41% | -13.48% | — |
| Earnings Growth % | 32.7% | -53.84% | 22.5% | — |
| Profit Margin % | -76.91% | -104.58% | -43.91% | -49.02% |
| Operating Margin % | -74.53% | -101.2% | -39.47% | -44.95% |
| Gross Margin % | -3.18% | -43.84% | -4.01% | -6.09% |
| EBITDA Margin % | -36.35% | -42.07% | 0.12% | -10.34% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-04-15 | 1:0.1 |
| 2024-03-06 | 1:0.2 |
| 2023-03-06 | 1:0.1 |